Multiple sclerosis-associated HLA demarcates EBV-specific CD8<sup>+</sup> T cells with an exhausted and brain residency phenotype.
Overview
- Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- MS Center ErasMS, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- Neuroimmunology Research Group, Netherlands Institute for Neuroscience, Amsterdam, the Netherlands
Abstract
In multiple sclerosis (MS), T cells could contribute to disease in their attempt to control the Epstein-Barr virus (EBV). Here, we compared the presence of HLA-B7 (higher MS risk) or HLA-A2 (lower MS risk) and investigated the effector phenotype of EBV epitope-specific CD8+ T cells in MS using spectral flow cytometry. In contrast to HLA-A2, HLA-B7-restricted CD8+ T cells recognized few EBV epitopes. These HLA-B7-restricted EBV-specific CD8+ T cells expressed CNS residency markers and were most abundant in postmortem CNS compartments of an HLA-A2+B7+ MS donor. HLA-B7-restricted EBV-specific CD8+ T cells displayed a more exhausted phenotype (PD-1+CD244+CD160+KLRG1+
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper says that its authors' code is available on request: it was not published with the paper, so there is nothing to verify.
The paper's code and data availability statement is in the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none (its code is available on request), so it has no map.
Data
No dataset and no data link were found in the paper.
Data and code availability
Data will be made available by the lead contact upon request. For sharing individualized data or material of participants who provided consent for sharing, a data transfer agreement (DTA) or material transfer agreement (MTA) needs to be developed as appropriate.
This study does not report original code.
Any additional information required to reanalyze the data reported in this study are available from the lead contact upon request.
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 29 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 14 authors, 1 keyword, 4 funders, 41 references, 38 RRIDs.
Cite
This paper
Reijm, S., Marques, A. M., Rip, J., Corsten, C. E., Wierenga-Wolf, A. F., de Wit, H., Melief, M.-J., van Hasselt, Y., van Langelaar, J., Neuteboom, R., Wokke, B. H., Mueller, Y. M., Smolders, J., & van Luijn, M. M. (2026). Multiple sclerosis-associated HLA demarcates EBV-specific CD8&
BibTeX
@article{reijm2026multip
author = {Reijm, Sanne and Marques, Ana M and Rip, Jasper and Corsten, Cato EA and Wierenga-Wolf, Annet F and de Wit, Harm and Melief, Marie-José and van Hasselt, Yifan and van Langelaar, Jamie and Neuteboom, Rinze and Wokke, Beatrijs HA and Mueller, Yvonne M and Smolders, Joost and van Luijn, Marvin M},
title = {{Multiple sclerosis-associated HLA demarcates EBV-specific CD8\&
journal = {iScience},
year = {2026},
month = apr,
volume = {29},
number = {5},
pages = {115744},
publisher = {Elsevier},
issn = {2589-0042},
doi = {10.1016/
url = {https://
pmid = {42111195},
pmcid = {PMC13157025}
}
RIS
TY - JOUR
AU - Reijm, Sanne
AU - Marques, Ana M
AU - Rip, Jasper
AU - Corsten, Cato EA
AU - Wierenga-Wolf, Annet F
AU - de Wit, Harm
AU - Melief, Marie-José
AU - van Hasselt, Yifan
AU - van Langelaar, Jamie
AU - Neuteboom, Rinze
AU - Wokke, Beatrijs HA
AU - Mueller, Yvonne M
AU - Smolders, Joost
AU - van Luijn, Marvin M
TI - Multiple sclerosis-associated HLA demarcates EBV-specific CD8&
T2 - iScience
J2 - iScience
PY - 2026
DA - 2026/
VL - 29
IS - 5
SP - 115744
SN - 2589-0042
PB - Elsevier
DO - 10.1016/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1016/
"type": "article-journal",
"title": "Multiple sclerosis-associated HLA demarcates EBV-specific CD8&
"container-title": "iScience",
"author": [
{
"family": "Reijm",
"given": "Sanne"
},
{
"family": "Marques",
"given": "Ana M"
},
{
"family": "Rip",
"given": "Jasper"
},
{
"family": "Corsten",
"given": "Cato EA"
},
{
"family": "Wierenga-Wolf",
"given": "Annet F"
},
{
"family": "de Wit",
"given": "Harm"
},
{
"family": "Melief",
"given": "Marie-José"
},
{
"family": "van Hasselt",
"given": "Yifan"
},
{
"family": "van Langelaar",
"given": "Jamie"
},
{
"family": "Neuteboom",
"given": "Rinze"
},
{
"family": "Wokke",
"given": "Beatrijs HA"
},
{
"family": "Mueller",
"given": "Yvonne M"
},
{
"family": "Smolders",
"given": "Joost"
},
{
"family": "van Luijn",
"given": "Marvin M"
}
],
"container-title-short":
"volume": "29",
"issue": "5",
"page": "115744",
"DOI": "10.1016/
"PMID": "42111195",
"PMCID": "PMC13157025",
"ISSN": "2589-0042",
"publisher": "Elsevier",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
15
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.3390/ijms27167275 [code]
- Integrative Multi-Omics Analysis of Multiple Sclerosis Reveals Cell-Type-Specific Regulatory Landscapes and Discordant Methylation-Expression Coupling.Journal: International journal of molecular sciencesIn common: multiple sclerosis, 2 references
- [2] doi:10.1186/s12951-026-04551-7
- The role of AI-assisted drug repurposing in neurological disorders: a systematic review of validation strategies, challenges and opportunities.Journal: Journal of nanobiotechnologyIn common: multiple sclerosis, 2 references
- [3] doi:10.1007/s00401-026-03062-x
- Genetic subtypes of multiple sclerosis severity are uncoupled from inflammatory lesion burden.Journal: Acta neuropathologicaIn common: multiple sclerosis, 2 references
- [4] doi:10.3389/fbinf.2026.1832826 [code]
- Spatial transcriptomics reveal heterogeneous cell‒cell interactions among brain regions in cuprizone model consistent with multiple sclerosis lesions.Journal: Frontiers in bioinformaticsIn common: multiple sclerosis, 2 references
- [5] doi:10.1186/s12974-026-03895-z [code]
- Multi-omics integration provides biological insight and prioritizes potential drug targets in multiple sclerosis progression.Journal: Journal of neuroinflammationIn common: multiple sclerosis, 2 references
- [6] doi:10.1038/s41586-026-10310-3 [code]
- DNA damage burden causes selective CUX2 neuron loss in neuroinflammation.Journal: NatureIn common: multiple sclerosis, 2 references
- [7] doi:10.1016/j.ebiom.2026.106324 [code]
- Refined single-cell profiling captures a CCR5&
lt;sup& gt;high& lt;/ sup& gt; CD4& lt;sup& gt;+& lt;/ sup& gt; cytotoxic T-cell precursor in multiple sclerosis. Journal: EBioMedicineIn common: multiple sclerosis, 2 references - [8] doi:10.1073/pnas.2519445123
- Multiple molecular mimics in Epstein Barr Nuclear Antigen-1, and the pathogenesis of multiple sclerosis.Journal: Proceedings of the National Academy of Sciences of the United States of AmericaIn common: multiple sclerosis, 1 reference
- [9] doi:10.1002/acn3.70458 [code]
- The Multiple Sclerosis Severity Allele rs10191329&
lt;sup& gt;A& lt;/ sup& gt; and Cognitive Function: A UK Biobank Study. Journal: Annals of clinical and translational neurologyIn common: multiple sclerosis, 1 reference - [10] doi:10.3389/fimmu.2026.1805464
- Chronic low-grade inflammation, genetic susceptibility, and the risk of multiple sclerosis: a prospective cohort study.Journal: Frontiers in immunologyIn common: multiple sclerosis, 1 reference
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.
Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.